Skip to main content
DXCM logo

DexCom, Inc. (DXCM) Stock: Price, Forecast & Analyst Target

DexCom, Inc. (DXCM) — MoonshotScore 93/100 (Exceptional band), calculated Nov 18, 2026. Price $80.19 (-2.82%), as of the Nov 19, 2026 trading session; market cap $29.9B. Expected results Feb 11, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$80.19 −$2.33 (-2.82%) Market Cap $29.9B

DexCom, Inc. · DXCM · NASDAQ · Healthcare · Medical - Devices

Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered): DexCom sells continuous glucose monitoring systems that connect glucose readings with diabetes treatment decisions, clinician workflows, remote monitoring, and digital health applications. Its case depends on whether expanding adoption can continue lifting revenue and profit while international pressure, operating spending, and a demanding valuation leave less room for execution setbacks.

Price as of Nov 19, 2026

Key Statistics

93 of 100

MoonshotScore v2 · DexCom (DXCM)

Exceptional
Business Quality Elite (94)
Financial Safety Sound (70)
Valuation Full (44)
Growth Durability Compounding (94)
Momentum Surging (84)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality, a strong balance sheet and elite growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.

  • quarterly revenue $1.34B (Q3 FY2026, quarter ended Sep 2026)
  • EPS beat 6 of the last 8 reports
  • expected results Feb 11, 2027

Helping: business quality, balance-sheet strength, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for DXCM (57 recorded, newest six shown)
RecordedScoreBand
94Exceptional
94Exceptional
94Exceptional
94Exceptional
93Exceptional
93Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$80.19
Change on the day-2.82%
52-week range$56.72–$92.59
Market capitalisation$29.9B—
Price / earnings (trailing)31.68
Shares traded on the day4.09M
Beta (volatility vs the S&P 500)1.44

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $55, high $92, latest $80. $92 $55 high $92 Oct 17, 2025 Nov 19, 2026 · $80 $67Oct 17, 2025$58Oct 31, 2025$58Nov 14, 2025$63Nov 28, 2025$67Dec 12, 2025$68Dec 26, 2025$67Jan 9, 2026$73Jan 23, 2026$70Feb 6, 2026$73Feb 20, 2026$68Mar 6, 2026$67Mar 20, 2026$62Apr 2, 2026$64Apr 17, 2026$61May 1, 2026$62May 15, 2026$74May 29, 2026$75Jun 12, 2026$70Jun 26, 2026$75Jul 10, 2026$72Jul 24, 2026$85Aug 7, 2026$92Aug 21, 2026$88Sep 4, 2026$89Sep 18, 2026$85Oct 2, 2026$86Oct 16, 2026$82Oct 30, 2026$83Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for DexCom (DXCM): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Moderate
Valuation Neutral
Growth Durability Strong
Momentum Strong

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Strong
Margin of Safety Fairly Valued
Profit Margin Moderate
Revenue Growth Moderate
Debt/Equity Neutral
ROE Strong
Gross Margin Strong

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 17, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is DexCom (DXCM), and what does it report?

Short answer · as of

DexCom is not simply a medical-device manufacturer shipping isolated hardware. Its portfolio combines continuous glucose monitoring systems with Dexcom Share remote monitoring, developer integrations, and direct commercial relationships with endocrinologists, physicians, and diabetes educators.

Reported revenue captures the consolidated economics of that connected monitoring portfolio across domestic and international markets. Annual sales and net income have advanced throughout the reported span, while research spending has remained substantial as DexCom develops and supports its glucose-monitoring platform.

2 · Latest results

What do the latest results show for DexCom (DXCM)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $1.34B.

The latest period extended the upward revenue trend and produced stronger gross profit, operating income, and net income. Gross profit expanded while research and commercial overhead rose more slowly than sales, allowing a larger share of incremental revenue to reach operating profit.

Revenue and reported earnings again exceeded market expectations, continuing a recent run of favorable revenue comparisons. Operating cash flow remained positive but eased from the preceding period, while management separately warned that international revenue would face a headwind relative to its prior outlook.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$1.34B$275M$0.72 (diluted)
Q2 FY2026$1.31B$249M$0.64 (diluted)
Q1 FY2026$1.19B$200M$0.51 (diluted)
Q4 FY2025$1.26B$267M$0.67 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for DexCom (DXCM)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

DexCom combines sustained profitability with positive operating cash flow, liquid resources above total debt, and favorable distress and financial-quality screens. Cash and investments provide meaningful flexibility for research and capital spending, while the trailing margins and returns show that the CGM platform is already economically productive.

The tension is that cash and short-term investments have declined across the reported window despite consistently positive operating cash flow. Continued cash contraction, slower CGM sales, or spending that begins outrunning gross-profit growth would weaken the current financial profile; the valuation premium would amplify the consequence of such deterioration.

4 · What to check next?

What should you watch next at DexCom (DXCM)?

Short answer · as of

The next earnings report is expected on Feb 11, 2027.

DexCom’s next release needs to preserve the recent combination of sales growth and operating leverage. Watch whether gross profit continues to outpace research and commercial overhead, whether revenue again clears expectations, and whether management’s anticipated international drag becomes visible in the consolidated result.

Cash conversion deserves equal attention. Operating cash flow has stayed positive, yet the liquid balance has moved lower over the broader window; stabilization would strengthen the profitability signal, while another material decline would demand scrutiny. Longer-range consensus expectations assume continued revenue and earnings expansion, raising the importance of execution against the next scheduled release.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does DexCom compare with its peers?

Short answer

DexCom's score ranks tied for 1st of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

DexCom differs from device businesses centered on isolated equipment because its offering connects continuous monitoring, treatment decisions, remote sharing, clinician relationships, and application integrations. That structure makes adoption and continued use of the broader CGM ecosystem more important than a conventional hardware shipment cycle.

The same model carries a distinct burden: DexCom must keep advancing the monitoring platform while sustaining commercial reach and protecting margins. Its sizable research commitment, strong profitability, and international exposure make product execution and geographic performance inseparable parts of the comparison with other medical-device companies.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
DexCom (DXCM) — this page$80.19$29.9B93
Edwards Lifesciences Corporation (EW) Same industry, near in market value$105.23 Nov 18, 2026$60.5B93 5-pillar Nov 18, 2026
Penumbra, Inc. (PEN) Same industry, near in market value$320.00 Nov 19, 2026$12.6B92 5-pillar Nov 18, 2026
STERIS plc (STE) Named competitor$259.57 Nov 18, 2026$25.2B87 5-pillar Nov 18, 2026
Insulet Corporation (PODD) Same industry, near in market value$139.98 Nov 18, 2026$9.71B85 5-pillar Nov 18, 2026
Smith & Nephew plc (SNN) Same industry, near in market value$30.32 Nov 18, 2026$12.7B84 5-pillar Nov 18, 2026
Align Technology, Inc. (ALGN) Same industry, near in market value$163.96 Nov 18, 2026$11.6B83 5-pillar Nov 18, 2026
Zimmer Biomet Holdings, Inc. (ZBH) Same industry, near in market value$103.32 Nov 18, 2026$19.6B79 5-pillar Nov 18, 2026
Koninklijke Philips N.V. (PHG) Named competitor$29.27 Nov 19, 2026$28.6B78 5-pillar Nov 18, 2026
Boston Scientific Corporation (BSX) Same industry, near in market value$43.64 Nov 18, 2026$63.3B77 5-pillar Nov 18, 2026
Bio-Rad Laboratories, Inc. (BIO) Same industry, near in market value$370.17 Nov 18, 2026$9.95B77 5-pillar Nov 18, 2026
Labcorp Holdings Inc. (LH) Named competitor$370.78 Nov 18, 2026$30.1B71 5-pillar Nov 18, 2026
Bruker Corporation (BRKR) Same industry, near in market value$62.10 Nov 19, 2026$9.48B59 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$86.00 – $115.00
Consensus target
$97.85
Median target
$96.00

Consensus record · Captured .

Measured against a quoted price of $80.19 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 8, 2026

Transactions
44
Identified insiders
17
Purchases
0
Sales
23
Other transactions
21

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held DXCM in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.13%$29.47MTrimmed −14.8% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about DexCom (DXCM)?

Read these with our analysis →

Common Questions About DXCM (Healthcare)

The last 2 questions are answered from this page's own dated data, not from the research.

What does Dexcom Share add to the company’s glucose monitors?

Dexcom Share extends the monitoring system into remote observation, allowing glucose information to reach people beyond the wearer. Alongside developer integrations, it makes DexCom’s offering a connected monitoring platform rather than isolated equipment.

Why does DexCom’s international outlook matter after its latest results?

Recent consolidated results showed rising revenue and profit, but management expects international revenue to face a drag relative to its earlier outlook. That pressure could test whether domestic momentum and operating leverage are strong enough to preserve the broader earnings trend.

Can DexCom fund continued investment in continuous glucose monitoring?

Liquid resources exceed total debt, and operating cash flow has remained positive while DexCom continues funding research and capital expenditures. The caution is that cash and short-term investments have declined across the reported window, so cash conversion matters alongside accounting profit.

What do recent DexCom insider transactions indicate?

Directional insider activity consisted of sales rather than purchases, alongside awards, gifts, and in-kind transactions. The pattern documents net selling but does not establish why individual insiders transacted.

What is the DXCM stock price today?

The last price recorded for DexCom, Inc. (DXCM), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the DXCM price target?

The analyst consensus price target for DexCom, Inc. (DXCM), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 20 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Business description; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Management outlook — dated call excerpts; Trailing twelve-month ratio set
  • 1. What is DexCom (DXCM), and what does it report?: Business description; Sector / industry (provider taxonomy); Annual revenue and net result (USD millions); Most recent periodic reports
  • 2. What do the latest results show for DexCom (DXCM)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for DexCom (DXCM)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set; Distress and quality screens; Cash against market value
  • 4. What should you watch next at DexCom (DXCM)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash decline over the reported window; Reported versus estimated, last 8 quarters; Next earnings report; Analyst revenue and earnings estimates (average); Management outlook — dated call excerpts
  • 5. How does DexCom compare with its peers?: Business description; Sector / industry (provider taxonomy); Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Trailing twelve-month ratio set; Management outlook — dated call excerpts
  • FAQ: What does Dexcom Share add to the company’s glucose monitors?: Business description
  • FAQ: Why does DexCom’s international outlook matter after its latest results?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • FAQ: Can DexCom fund continued investment in continuous glucose monitoring?: Cash, investments and debt; Cash and investment components; Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash decline over the reported window
  • FAQ: What do recent DexCom insider transactions indicate?: Insider transactions, last 180 days; What the sources do not tell us
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold DXCM

Funds in our ETF coverage that list DXCM among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
The Obesity ETF (SLIM)13.38%
LGHT ETF5.39%
Putnam Sustainable Future ETF (PFUT)2.37%
First Eagle Mid Cap Equity ETF (FEMD)1.69%